Our new ADCC Biospectrum for assessment of ADCC is tailored to your needs for extremely sensitive and biologically relevant results. The ADCC Biospectrum offers a fast, cost effective and reliable assessment of biosimilarity using:
- Genotyped donors
- Multiple effector cell preparations
- Disease state effector cell options
- Biologically relevant matrix formulations
- Extreme sensitivity to various glycan species
Designed to augment traditional ADCC methods, the ADCC Biospectrum utilises innovative techniques to detect clinically relevant differences between innovator and biosimilar drugs. Our assays support fingerprint-like similarity assessments, delivering highly sensitive and quality results.